Bacterin Announces 3Demin Cortical Fibers

Bacterin International Holdings, Inc. (NYSE MKT:

), a leader in the development of bone graft material and coatings for medical applications, today announced the launch of a demineralized allograft, 3Demin™ Cortical Fibers. 3Demin™ Cortical Fibers are the first product released in Bacterin's latest 3Demin™ product family, and the second new product launched this year. 3Demin™ allografts may be used in a number of orthopedic and reconstructive applications, particularly spinal procedures. The fibers are demineralized using Bacterin's proprietary processing technology and have excellent regenerative properties for healing bone. The bone replacement market opportunity was estimated at $1.7 billion in 2013. The 3Demin™ Cortical Fibers have been launched to a limited number of surgeons and health facilities for market feedback which has been encouraging. The 3Demin™ product family will enhance Bacterin's existing biologic portfolio, and will provide an additional stream of revenue in the latter part of 2014 and into 2015.